agonists such as adenosine diphosphate (ADP) and thromboxanes, exposure of phosphatidylserine and upregulation of fibrinogenbinding capacity by the platelet-specific integrin αIIbβ3. This process has been described extensively in a number of recent reviews. [8] [9] [10] [11] The process of primary hemostasis is governed by the plateletspecific adhesion/signalling proteins glycoprotein (GP) Ib-IX-V and GPVI which predominantly bind von Willebrand factor (VWF) and collagen, respectively. 12 Both receptors can engage with other ligands, however, engagement of these receptors by VWF and collagen coordinate the platelet response to exposed subendothelial matrix across a range of vascular flow rates. As GPVI and the GPIb-IX-V complex cooperate and coordinate the platelet adhesionsignaling response, the relative densities of these receptors on the membrane are important for efficient and effective function. 13, 14 This review will discuss molecular mechanisms that rapidly alter the densities of these primary platelet adhesion receptors and influence capacity of platelets to respond. The review will also consider how the same mechanisms modulating platelet and other vascular cell receptors may contribute to vascular inflammation.
| GPIb-IX-V
The GPIb-IX-V complex consists of GPIbα disulphide linked to GPIbβ and noncovalently linked to GPIX and to GPV. All four subunits of the complex are members of the leucine-rich repeat family of proteins however the N-terminal portion of GPIbα is the major ligandbinding region of the complex (Figure 1 ). Within the leucine-rich repeat domain of GPIbα, repeats 2-4 (amino acids 60-128) play a crucial role in regulating adhesion to VWF under shear conditions. 15, 16 The ectodomain of GPIbα is essential for thrombus formation 17 and likely also for other aspects relating to the role of platelets in coagulation and innate immunity responses as this portion of the receptor complex is able to bind a number of key molecular players in these critical pathways. 18 Apart from both plasma and extracellular matrix VWF, other GPIbα binding partners include coagulation proteins factors XI and XII, thrombin, thrombospondin, and highmolecular-weight kininogen, the leukocyte integrin αMβ2, and P-selectin, found on activated platelets and endothelial cells. The ectodomain of GPIbα also associates with the extracellular portion of the platelet collagen receptor GPVI 19 (see below) and this interaction influences how collagen engages GPVI. 19, 20 Whilst the binding sites within GPIbα for these ligands remain to be fully described, all of these binding proteins engage the extracellular region of GPIbα.
The consequences of VWF binding to the GPIb-IX-V complex has remained a matter of some debate; however, if the A1 domain (the GPIbα-binding portion of VWF) is presented to the platelet in an appropriate context, this binding interaction can generate powerful intracellular phosphorylation events. 21 The cytoplasmic tail portions of GPIbα and GPIbβ associate directly with components of the platelet cytoskeleton including actin, and α-actinin, and engagement of GPIb-IX-V by VWF leads to actin polymerisation, an event that is sensitive to the level of shear stress to which the platelet surface is exposed. 22 GPIb-IX-V also contains sequences which bind 14-3-3ζ at the GPIbα C-terminus, as well as protein kinase A, tissue necrosis factor-alpha receptor-associated factor (TRAF)-4, and calmodulin binding sites on GPIbβ. [23] [24] [25] 14-3-3ζ in association with phosphoinositol 3-kinase 26 regulates the VWF-binding affinity of GPIb-IX-V and inhibiting 14-3-3ζ association blocks receptor signalling. 
| GPVI
GPVI is one of a number of platelet membrane proteins that can bind collagen (others include GPV, CD36 and α2β1)
27
; however, it is regarded as the major receptor for collagen as this receptor rapidly triggers powerful intracellular signalling events and activating pathways that enable the platelet to respond and adhere to collagen 28 ( Figure 1 ).
GPVI is a member of the immunoglobulin (Ig)-like superfamily of adhesion proteins and contains two extracellular Ig-like domains. Within the cytoplasmic tail region, GPVI has a calmodulin-binding sequence 29 and a sequence which binds TRAF-4. 25 Surface expression of GPVI requires the tandem expression of the Fc receptor (FcR) γ chain, an ~10-kD protein that links with GPVI via a salt bridge within the plasma membrane.
The cytoplasmic domain of FcRγ contains an immunoreceptor tyrosine activation motif (ITAM) and together the GPVI/FcRγ complex transmits ligand-induced signalling events into the platelet by triggering phosphorylation of two tyrosine residues with the ITAM and subsequent activation of p72-spleen tyrosine kinase (Syk). 28 Along with collagen, GPVI can bind laminin, 30 fibrin, 31, 32 fibrinogen, 33, 34 histones, 35 adiponectin, 36 and the extracellular matrix metalloproteinase inducer (EMMPRIN) 37 expressed on monocytes and leukocytes. Intact GPVI is also essential for efficient generation of thrombin at the platelet surface. 31 The best characterized GPVI interaction is with collagen. When engaged by collagen, both the intracellular 38 and extracellular 39 regions of GPVI/FcRγ can dimerize and this is likely to aid and enhance the clustering of the receptor, 40 and bring ITAMs within the cytoplasmic tail of GPVI/FcRγ together. This triggers tyrosine phosphorylation of members of the Src family of kinases leading to upregulation of phosphoinositide (PI)-3 kinase activity and integrin activation. As the ectodomains of GPVI and
GPIbα are co-associated on the platelet membrane, 19 it is reasonable to believe that these two adheso-signaling proteins display a level of functional cooperation and coordinated output across a range of shear and ligand exposure conditions. Interestingly, the ectodomain of GPIbα can modulate the rate and extent of activation of platelets by collagen 20 and collagen-related peptide. 19 In particular, anti-GPIbα monoclonal antibodies that target the anionic sulphated tyrosine region of GPIbα (amino acids 269-282) interfere with platelet responsiveness to these GPVI ligands. This was not related to any specific antibody property as specific removal of the GPIbα ectodomain by treatment with the snake venom protein mocarhagin also ablated collagen-related peptide-induced aggregation. 19 By altering one or both of the ligand binding regions of GPVI and GPIbα, platelet responsiveness particularly to collagen is likely to be modulated.
| PLATELET ADHESION RECEPTORS FUNCTION UNDER FLUID SHEAR STRESS
The engagement of the GPIb-IX-V complex by VWF and VWF/collagen occurs in flowing blood and is an exquisite example of a shear-sensitive interaction. The interaction occurs through immobilized VWF partially unfolding under fluid shear and enabling a region within the A1 domain of VWF to be accessible and interact with the N-terminal portion of the GPIbα subunits within the complex. 41 This complex interaction occurs and is sustained under a range of shear stress rates via specialized bonds that are sensitive to shear stress and this interaction directly impacts on the rate and extent of platelet activation. 42, 43 GPIbα also senses and responds to changes in fluid shear stress and whilst the mechanisms by which this subunit of the GPIb-IX-V complex alters its affinity for VWF remain to be elucidated, regions within the GPIbα ectodomain that do not overlap with the VWF ligand binding region have been identified to influence both the affinity of the receptor for ligand and the ability of the receptor complex to maintain VWF binding under fluid shear stress. These include a region within leucine-rich repeats 6 and 7 44 and a mechanosensing domain within the extracellular juxtamembrane region of GPIbα. 45 The former was identified as binding a cyclic peptide termed OS-1, identified by phage display to act as an allosteric inhibitor of VWF-GPIbα interactions. 44 The latter is a region spanning ~60 amino acids lying between the macroglycopeptide and transmembrane domain of GPIbα, which unwinds in response to pulling of prebound VWF A1 domain, as demonstrated in experimental systems using optical tweezers. 45 Both studies illustrate the potential of nonligand binding ectodomain regions of the GPIbα subunit to influence and promote ligand binding capacity and affinity, and potentially stabilize receptor ligand interactions at fluid shear rates found in the vasculature.
GPVI plays an important role in hemostasis and thrombosis through integrin activation, supporting adhesion and the initial stages of platelet aggregation. However, patients and mice with platelets lacking GPVI show only a mild bleeding diathesis [46] [47] [48] most likely due to the existence of compensatory pathways that generate thrombin and that lead to platelet activation independent of GPVI. 49 However, the situation is different under thrombotic conditions where mice with platelets lacking GPVI are protected against arterial thrombosis and subsequent neointima formation 50 and demonstrate an impaired thrombus formation at high shear rates. 51 GPVI is likely to contribute significantly to stable thrombus formation as the ectodomain is important for efficient thrombin formation 31, 52 and GPVI-fibrin interactions are likely to stabilize a forming thrombus under shear stress. 31, 32 Clinical therapies that target platelet responsiveness (antiplatelet therapy) can successfully reduce cardiovascular events, especially in people at higher risk; however, all current antiplatelet therapies carry an increased probability of bleeding. Because loss of GPVI does not result in major hemostatic complications, the therapeutic potential of targeting GPVI is an exciting area that is being actively explored. [53] [54] [55] Anti-GPVI antibodies, particularly single domain antibody clones and fragment antigen-binding (Fab) fragments may be useful candidate antithrombotic reagents 56,57 as they could potentially interfere with collagen-GPVI interactions and trigger metalloproteolytic GPVI shedding and/or internalization.
| METALLOPROTEINASE-MEDIATED RECEPTOR SHEDDING
Along with triggering fibrinogen binding to the major platelet integrin αIIbβ3, activation of pathways from both the GPIb-IX-V complex and GPVI leads to a rapid and irreversible metalloproteinase-mediated cleavage of the ligand-binding ectodomains of GPIbα, GPV, and and an ~55-kDa GPVI fragment 59 from human platelets. The extracellular region of GPV is also released by the action of thrombin to produce an ~20-kDa platelet-associated fragment 59, 64 and by metalloproteolytic cleavage of the complete extracellular region to leave an ~5-kDa remnant fragment. 59 This process is clearly different from other forms of receptor removal which involve either the export of receptors from the plasma membrane via packaging in extracellular vesicles 65 such as occurs with platelet and endothelial P-selectin, or internalization processes whereby receptors are either moved to ligand-inaccessible surface-connected canalicular storage pools or degraded. 66, 67 In contrast to GPIbα which appears to be constitutively shed, 18, 68 GPVI is stable on the surface of circulating nonactivated platelets 59, 60 with no evidence of a platelet-associated 10-kDa remnant fragment. This supports the use of intact and soluble GPVI as platelet-specific markers of activation. 69 
| PLATELET METALLOPROTEINASES
The receptor and bioactive protein shedding process is mediated by members of the A Disintegrin And Metalloproteinase (ADAM) family with prominent roles for ADAM10 and ADAM17 across biology.
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The ADAMs family of metalloproteinases ( Figure 3 ) has more than 40 members and most members share a basic domain structure consisting of an N-terminal prodomain followed by a catalytic, a disintegrin, and a cysteine-rich domain. Most family members contain epidermal growth factor-like domains (although ADAM10 and ADAM17 do not) followed by a single pass transmembrane domain and a short cytoplasmic tail. 72, 73 ADAM10 and ADAM17 are both found on the membrane of resting platelets and these enzymes mediate the cleavage of GPVI and GPIbα, respectively. In murine platelets, shedding of these receptors may involve contributions from both ADAM10 and ADAM17. 74 ADAMs proteinases, particularly ADAM10 and ADAM17 are broadly expressed across a variety of cell types, both at the cell surface and in intracellular granules as zymogens. The prodomain is removed from immature ADAMs prior to being brought to the cell surface as mature catalytically active proteins. 72 However, on platelets, mature ADAM10 and ADAM17 both seem to be constitutively present at the platelet surface, and in the case of ADAM10 at least, have detectable proteolytic activity. 75 The crystal structure of the ADAM10 ectodomain was recently solved 76 and revealed a compact arrangement of the domains permitting intrinsic autoinhibition of the catalytic domain within the mature protein by the disintegrin and cysteine-rich domains and preventing substrate access to the metalloproteinase active site. This suggests that there is a level of control of ADAM10 activity at a membrane surface, under resting conditions.
Platelet granules also contain a number of members of the matrix metalloproteinase (MMP) family. Both of these regions regulate the availability of the ADAM17 cleavage site within GPIbα to metalloproteases such as ADAM17 and so aid in control of GPIbα levels. In response to ligand engagement, exposure to elevated shear or during coagulopathy, GPVI is proteolytically cleaved from the platelet surface. In a system that is reminiscent of the classical ADAM17-mediated shedding of leukocyte L-selectin, 98 detachment of calmodulin from the cytoplasmic juxtamembrane binding site, either by ligand engagement or by treatment of platelets with an inhibitor of calmodulin, triggers the release of the GPVI ectodomain. 60 In the following sections, the mechanisms most relevant to physiological shedding of platelet receptors will be discussed, with a focus on the regulation of platelet GPVI levels.
| TRIGGERS OF PLATELET RECEPTOR SHEDDING

| Laboratory approaches
There are various ways that proteolytic release of GPVI can be W7 results in detachment of receptor-bound calmodulin and triggers shedding of GPVI, GPV, and GPIbα. 102 Interestingly, the W7 mechanism of action does not increase the endogenous platelet ADAM10 activity, 75 suggesting that calmodulin dissociation alters the availability of the ADAM10 cleavage site within GPVI. These reagents are highly useful laboratory tools that have enabled rapid evaluation of ADAMs structure and catalytic potential for a huge range of substrates in both primary cell culture and in cell lines. In platelets, these reagents have broad utility, particularly NEM where treatment of washed platelets or platelet-rich plasma for 15-30 minutes with 5 mmol L −1 NEM is sufficient to liberate greater than 90% of GPVI and so permit an assessment of GPVI shedding potential across blood donor populations, as well as create a GPVI-deficient platelet to aid in the assessment of plateletactivating plasma components. 103 An additional means to remove GPVI from the surface of platelets that has been put to excellent use in mouse models of thrombosis and hemostasis is the use of anti-GPVI antibodies. 104 
| Exposure to GPVI ligands
Fibrillar collagen type 1 is the major collagen type that engages GPVI. Together with collagen type 3, it is the predominant collagen found in the subendothelium in the blood vessel wall. 107 and studies have demonstrated that while fibrin-GPVI interaction will generate intracellular signals, 32,108 this signalling is not required for fibrin-induced GPVI shedding. 109 The fibrin interaction with GPVI is mediated by the D-dimer region of fibrin 33, 108 and for GPVI shedding to occur, fibrin must be polymerized. 109 Whether fibrin can bind platelet GPVI monomer or dimer 33, 108 remains a matter for debate; however, dimeric GPVI-Fc fusion proteins do not engage fibrin. 110 Similarly, the fibrin-binding site within GPVI is contentious.
In one study, the GPVI-fibrin interaction occurred only with GPVI in dimeric form and could be abrogated by pretreatment with collagen or CRP, implying at least partial overlap of the binding site for these ligands, 33 however, fibrin-GPVI monomer interactions and separate CRP and fibrin binding sites were proposed in another study. 108 Under certain experimental conditions and in collaboration with αIIbβ3, the fibrin monomer component fibrinogen also can engage GPVI. 33, 34 Understanding how these two GPVI ligands intersect and contribute to GPVI function is important, as selective disruption of one type of GPVI-ligand interaction, either through competitive inhibition at the ligand-binding site, or at the level of GPVI dimerization represents an enticing new approach to develop antiplatelet agents with minimal effects on hemostasis.
| Activation of coagulation
Through comparison of sGPVI levels in matched plasma and serum samples from healthy donors, it emerged that GPVI shedding can be triggered by coagulation. 
| Exposure to elevated fluid shear stress
Human platelets normally circulate in a resting state and are exposed to shear rates within a physiologic range (~20-2000 s −1 ). 11, 112, 113 Platelets may encounter shear rates well beyond 10 000 s VWF multimers. [115] [116] [117] This loss may combine with other diseaserelated vascular factors and contribute to the high rate of serious bleeding seen in this patient cohort. 118 Whether measurement of sGPVI levels in plasma samples taken prior to implantation will enable stratification of patients into low-and high-risk bleeding groups 115 and the opportunity to tailor antiplatelet and anticoagulant therapy is the subject of ongoing research.
| Antiplatelet antibodies and autoantibodies
In primary immune thrombocytopenia (ITP) and in heparininduced thrombocytopenia (HIT), patients generate antibodies that are reactive with antigens on the surface of platelets and megakaryocytes. In ITP, these antibodies disrupt megakaryocytopoiesis, induce platelet apoptosis or opsonise the surface of the platelet enhancing the rate of clearance of platelets by the liver and spleen. 119 In at least a subset of patients, antibody binding to platelet surface antigens including GPIbα, αIIbβ3, and α2β1 leads to engagement of platelet FcγRIIa by the Fc portion of the autoantibody. In ITP patients with anti-GPVI autoantibodies, the loss of responsiveness to collagen by light transmission aggregometry, loss of platelet GPVI by flow cytometry, or enhanced GPVI shedding has been demonstrated. 103, [120] [121] [122] In this pathological scenario, autoantibody-mediated GPVI loss may involve signalling contributions from both GPVI and FcγRIIa. In HIT, autoantibodies that recognise platelet factor-4 in combination with heparin, form immune complexes which also engage FcγRIIa. 123 FcγRIIa is a second ITAM-containing signalling receptor, and this binding can trigger significant platelet activation and platelet clearance 124 as well as activation of GPVI shedding pathways. 125 
| CONCLUSION
Metalloproteolysis of receptor ectodomains is a regulatory mechanism that is common to many cell types across cell biology (Figure 4 ).
In some cases, this mechanism liberates a bioactive portion of a latent factor, while in others cases, it is a means of controlling the reactive or adhesive properties of a cell or enabling the cell to sense its surroundings. In platelets, the release of the ligand binding portions of GPVI and GPIbα are likely to modulate the densities of each of these cooperating receptors, parameters that are important for the adhesive properties of the platelet. When using platelets from mice deficient in their subtle receptor density changes act to limit thrombus growth and propagation of coagulation at the site of thrombus formation. However, beyond these outcomes that are critical for hemostasis, and in keeping with the burgeoning roles for platelets in innate immunity and inflammation, loss of these ectodomains are also likely to influence how platelets engage with other cells such as leukocytes and endothelial cells as well as tumor cells. 126 Indeed, modulation of receptor levels on the surface of platelets is likely to be critical for new avenues of research where platelets are demonstrated to undergo diapedesis 127 and in the utility of platelets for delivery of therapies to critical sites of injury, inflammation, and metastasis.
128,129
RELATIONSHIP DISCLOSURE
The author has no conflicts of interest to declare.
ORCID
Elizabeth E. Gardiner http://orcid.org/0000-0001-9453-9688
